Tempus, a leader in artificial intelligence and precision medicine, today announced that City of Hope Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers represents over 30 medical centers that are leveraging the program to advance its research.
Researchers at City of Hope are leveraging Tempus’ library of more than six million de-identified research records to power and validate clinical research. Through Tempus’ data analytics platform, Lens, researchers have the opportunity to define insights through the company’s molecular, phenotypic, treatment, and outcomes data, and identify patterns and insights, define and test hypotheses, and eventually investigate and potentially publish their research.
“Tempus+ provides a platform for researchers to interrogate the complex molecular state of cancer. The data is invaluable in understanding cancer biology, especially the development of better prognostic and predictive biomarkers,” said Marwan Fakih, MD, Professor, Medical Oncology Division Head, GI Medical Oncology, Associate Director for Clinical Sciences. “This comprehensive database is easy to navigate and allows investigators from various institutes to generate hypothesis-generating data or to validate pilot data generated from prior limited data sets.”
“This is just the start of the potential of our collaboration with the team at City of Hope,” said Mike Thompson, MD, PhD, Vice President of Clinical Partnerships at Tempus. “They share our belief in the power of data in furthering clinical care and research in oncology and beyond.”
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.